

## **ULCERATIVE COLITIS AND CROHN'S AUTHORIZATION AND RE-AUTHORIZATION REQUEST**

15 Earhart Drive, Suite 101, Amherst, NY 14221  Member Name:				TEL: (716) 929-1000   1-800-809-4763 FAX: (716) 532-7360				
Date of birth: Sex: Weight:				Today's Date:  Prescriber: Specialty:				
	vveignt.			one Number:				
Home Phone Number:			Pno	Phone Number: Fax Number:				
Home Address/City/State/Zip:			Offi	Office Address/City/State/Zip:				
Payor: ☐ Commercial ☐ Medicare			Not	Notes:				
<ul> <li>☐ Independent Health</li> <li>☐ Anne Arundel Health System</li> <li>☐ Pharmacy Benefit Dimensions</li> </ul>	☐ Medicaid	☐ Self-funded	Allergies:					
Insurance ID:	Group Number:		ls p	oatient self-injecti	ing? □ Yes □ N	Ю		
STATEMENT OF MEDICAL NECESSITY				DRUG SELECTION  □ New Authorization Request □ Reauthorization Request				
				□ New Autr	ionzation Reque	esi 🗆 Reaui	nonzation Request	
ICD 10 Code Prim	ary Diagnosis:							
ICD 10 Code Primary Diagnosis:				Ulcerative Colitis:				
TB Skin Test Result: Date:					□ HUMIRA □	REMICADE		
				□ SIMPONI □	XELJANZ	HADLIMA	(ADALIMUMAB-BWWD)	
Has the patient tried and failed to respond to a 3 month trial of 1 of the			ne	□ ADALIMUM	AB-ADAZ 🗆	OTHER		
below conventional agents?	·							
(Methotrexate, Azathioprine, Amin			ie,					
corticosteroids (including budesonide EC capsule), Metronidazole, Cyclosporine, Ciprofloxacin)				Crohn's Disease				
□ Yes □ No								
□ res □ No				☐ STELARA			VIO	
If yes, please prior treatments and dates				☐ HUMIRA	☐ REMICADE	⊟ HADL	IMA (ADALIMUMAB-BWWD)	
				□ ADALIMUMAB-ADAZ □ OTHER				
Other Prior Treatments			_	□ Initial	Dose:			
For Ulcerative Colitis or Crohn's	s Disease reauth	orization:						
-Does patient continue to meet initiation criteria including ongoing TB monitoring? $\hfill\Box$ Yes $\hfill\Box$ No				☐ Maintenance Dose:Frequency:				
-ls patient in absence of toxicity fro	om the drug?	□ Yes □ I	No					
-Has the patient shown a clinical r	esponse of remiss	sion? □ Yes □	No					